Clinical Trials
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S1803
Phase III Study of Daratumumab (NSC- 791647) + Lenalidomide (LD) or Lenalidomide (L) as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Status Notes
This study is open to patient accrual effective 6/27/19.
Research Committee(s)
Myeloma
Activated
06-27-2019
Open
Accrual
0%
SWOG Clinical Trial Number
S1916
Feasibility of a Digital Medicine Program in Optimizing Opioid Pain Control in Cancer Patients
Status Notes
This is being distributed for IRB review only.
Research Committee(s)
Cancer Care Delivery
Activated
06-11-2019
Open
SWOG Clinical Trial Number
CTSU/NHLBI-MDS
The National Myelodysplastic Syndromes (MDS) Study
Research Committee(s)
Prevention & Epidemiology
Leukemia
Activated
06-01-2019
ClinicalTrials.gov Registry Number
NCT02775383
Open
Accrual
5%
SWOG Clinical Trial Number
S1800A
A PHASE II RANDOMIZED STUDY OF RAMUCIRUMAB PLUS MK3475 (PEMBROLIZUMAB) VERSUS STANDARD OF CARE FOR PATIENTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP NON-MATCHED SUB-STUDY)
Status Notes
S1800A will open to accrual May 17, 2019, effective 11:00 am PST.
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Lung Cancer
Activated
05-17-2019
Open
Phase
III
Accrual
1%
SWOG Clinical Trial Number
S1806
Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.
Research Committee(s)
Genitourinary Cancer
Activated
04-19-2019
Open
SWOG Clinical Trial Number
CTSU/NRG-BR004
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/ Trastuzumab/ Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Status Notes
Activated by NRG: 3/12/19.
Activated by SWOG: 4/1/19.
Activated by SWOG: 4/1/19.
Activated
04-01-2019
ClinicalTrials.gov Registry Number
NCT03199885